Related Experiment Videos
[Arrhythmias in cardiomyopathies]
Yoshiaki Kaneko1, Masahiko Kurabayashi
1Second Department of Internal Medicine, Gunma University School of Medicine.
Insights
This review covers sudden cardiac death risk in dilated, hypertrophic, and arrhythmogenic cardiomyopathies. It highlights risk factors and treatments like amiodarone and implantable cardioverter-defibrillators for prevention.
Area of Science:
- Cardiology
- Electrophysiology
- Genetics
Context:
- Focuses on three primary cardiomyopathies: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC).
- Addresses the critical issue of complicated arrhythmias and sudden cardiac death (SCD) within these conditions.
- Emphasizes the need for precise risk stratification to identify high-risk patient groups.
Purpose:
- To review the pathophysiology of arrhythmias and SCD in DCM, HCM, and ARVC.
- To discuss current risk stratification methods and therapeutic strategies for these cardiomyopathies.
- To inform clinical practice regarding the prevention of sudden cardiac death.
Summary:
- Pathophysiology of arrhythmias and SCD in DCM, HCM, and ARVC is detailed.
- Risk factors for SCD are identified for each cardiomyopathy type.
- Current treatment options, including amiodarone and implantable cardioverter-defibrillators (ICDs), are presented as preventive measures.
Impact:
- Aims to improve the identification and management of patients at risk for sudden cardiac death.
- Provides a consolidated overview of current knowledge for clinicians and researchers.
- Contributes to the reduction of mortality associated with cardiomyopathies through targeted therapeutic interventions.
Abstract:
The purpose of this review is to discuss the pathophysiology of the complicated arrhythmias or sudden cardiac death, the appropriate risk stratification and current treatment options in patients with dilated cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. It is important to know possible risk factors on risk stratification for a high-risk group in each cardiomyopathy. Therapeutic strategies, including amiodarone, implantable-cardioverter-defibrillator, may contribute the prevention of sudden cardiac death.